PTIXW VS CYTO Stock Comparison

Performance

PTIXW
10/100

PTIXW returned -30.00% in the last 12 months. Based on SPY's performance of -13.78%, its performance is below average giving it a score of 10 of 100.

CYTO
10/100

CYTO returned -98.21% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Profit

PTIXW
10/100

Out of the last 20 quarters, PTIXW has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CYTO
13/100

Out of the last 20 quarters, CYTO has had 2 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

PTIXW
67/100

PTIXW has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.

CYTO
25/100

CYTO has had a lower than average amount of volatility over the last 12 months giving it a score of 25 of 100.

Technicals

PTIXW

"Technicals" not found for PTIXW

CYTO
14/100

CYTO receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

PTIXW

"Earnings" not found for PTIXW

CYTO
44/100

CYTO has missed earnings 2 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

Protagenic Therapeutics, Inc. Warrant Summary

Nasdaq / PTIXW

Healthcare

Biotechnology

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) Summary

Nasdaq / CYTO

Healthcare

Biotechnology

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Power up your portfolio